Plerixafor, an analog of C-X-C motif chemokine receptor 4 (CXCR4), which allows the release of stem cells from the bone marrow into peripheral blood (PB) by disrupting the interaction of CXCR4 with stromal cell-derived factor-1 (SDF-1), is effective in mobilization for peripheral blood stem cells (PBSC). Due to its market approval has not been long and its high price in China, the clinical application of plerixafor is still very limited. The clinicians are actively seeking the optimal use of plerixafor to improve the success rate of PBSC collection and reduce the cost. This article reviews the latest research progress related to plerixafor application, in order to summarize the optimal use of plerixafor in autologous hematopoietic stem cell transplantation (auto-HSCT).
题目: 普乐沙福在自体移植外周血干细胞动员中应用策略的研究进展.
摘要: 普乐沙福（plerixafor）是一种小分子趋化因子受体4（CXCR4）类似物，通过阻断基质细胞衍生因子-1 （SDF-1）和CXCR4的相互作用，将造血干细胞从骨髓释放入外周血，用于外周血干细胞（PBSC）动员。由于plerixafor在国内获批上市时间较短且价格昂贵，临床应用经验较少。临床研究人员正积极探索plerixafor的最佳使用策略，提高动员采集成功率并且降低成本。本文对近几年来plerixafor应用策略的最新研究进展作一综述，总结plerixafor在自体造血干细胞移植（auto-HSCT）中的最佳应用策略。.
Keywords: auto-HSCT; lymphoma; mobilization; multiple myeloma; plerixafor.